By continuing to browse the site you are agreeing to our use of cookies and similar tracking technologies described in our privacy policy.

AASLD Logo
IDSA Logo
Resource Library
  • Home
    • Table of Contents
    • Introductions
    • Methods
      • Methods Table 1
      • Methods Table 2
      • Methods Table 3 Abbreviations
    • References
  • Test, Evaluate, Monitor
    • Testing and Linkage to Care
    • When and in Whom to Initiate HCV Therapy
    • Cost, Reimbursement, and Cost-Effectiveness
    • Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy
    • Incomplete Adherence
    • HCV Resistance Primer
  • Treatment-Naive
    • Simplified: No Cirrhosis
    • Simplified: Compensated Cirrhosis
    • Decompensated Cirrhosis
    • Genotype 1
      • GT1a: No Cirrhosis
      • GT1a: Compensated
      • GT1b: No Cirrhosis
      • GT1b: Compensated
    • Genotype 2
      • GT2: No Cirrhosis
      • GT2: Compensated
    • Genotype 3
      • GT3: No Cirrhosis
      • GT3: Compensated
    • Genotype 4
      • GT4: No Cirrhosis
      • GT4: Compensated
    • Genotype 5 or 6
  • Treatment-Experienced Patients
    • SOF-Based and ELB/GRZ Treatment Failures
    • G/P Treatment Failures
    • Multiple DAA Treatment Failures
    • Decompensated Cirrhosis
  • Unique & Key Populations
    • HIV/HCV Coinfection
    • Decompensated Cirrhosis
    • Post Liver Transplant
    • Organs from HCV-Viremic Donors
    • Renal Impairment
    • Kidney Transplant
    • Acute Infection
    • HCV in Pregnancy
    • HCV in Children
    • PWID, MSM & Corrections
      • People Who Inject Drugs
      • Men Who Have Sex With Men
      • Correctional Settings
  • About
    • Announcements
    • Supporting Organizations
    • HCV Guidance Panel
    • Disclosures
    • Process
    • Citing and Permissions
    • Website Policies
    • Contact Us
AASLD Logo
IDSA Logo
    • Table of Contents
    • Introductions
      • Methods Table 1
      • Methods Table 2
      • Methods Table 3 Abbreviations
    • References
    • Testing and Linkage to Care
    • When and in Whom to Initiate HCV Therapy
    • Cost, Reimbursement, and Cost-Effectiveness
    • Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy
    • Incomplete Adherence
    • HCV Resistance Primer
    • Simplified: No Cirrhosis
    • Simplified: Compensated Cirrhosis
    • Decompensated Cirrhosis
      • GT1a: No Cirrhosis
      • GT1a: Compensated
      • GT1b: No Cirrhosis
      • GT1b: Compensated
      • GT2: No Cirrhosis
      • GT2: Compensated
      • GT3: No Cirrhosis
      • GT3: Compensated
      • GT4: No Cirrhosis
      • GT4: Compensated
    • Genotype 5 or 6
    • SOF-Based and ELB/GRZ Treatment Failures
    • G/P Treatment Failures
    • Multiple DAA Treatment Failures
    • Decompensated Cirrhosis
    • HIV/HCV Coinfection
    • Decompensated Cirrhosis
    • Post Liver Transplant
    • Organs from HCV-Viremic Donors
    • Renal Impairment
    • Kidney Transplant
    • Acute Infection
    • HCV in Pregnancy
    • HCV in Children
      • People Who Inject Drugs
      • Men Who Have Sex With Men
      • Correctional Settings
    • Announcements
    • Supporting Organizations
    • HCV Guidance Panel
    • Disclosures
    • Process
    • Citing and Permissions
    • Website Policies
    • Contact Us
Resource Library
  • Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the US Preventive Services Task Force

    May 3, 2017
  • Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis

    May 3, 2017
  • Hepatitis C virus infections in the Swiss HIV cohort study: a rapidly evolving epidemic

    May 3, 2017
  • Validation of a strategy for HCV antibody testing with two enzyme immunoassays in a routine clinical laboratory

    May 3, 2017
  • Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men

    May 3, 2017
  • Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic

    May 3, 2017
  • Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization

    May 3, 2017
  • Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis

    May 3, 2017
  • Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study

    May 3, 2017
  • A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin

    May 3, 2017
Previous Page
1 2 3 4 … 13
Next Page
AASLD Logo
IDSA Logo
  • Test, Evaluate, Monitor
  • Treatment-Naive
  • Treatment-Experienced Patients
  • Unique & Key Populations
  • Resource Library
  • About Us
  • Announcements
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Accessibility

© 2025 HCV Guidelines All right reserved.

Website by Yoko Co